Trevi gets $50M and David Meeker as its new chairman; Spark in line for a PRV
→ Trevi Therapeutics in New Haven, CT has raised a $50.5 million C round. The biotech has been pushing a drug called Nalbuphine ER through mid-stage trials, gathering data on its ability to reduce itching caused by a range of conditions. And former Sanofi-Genzyme chief David Meeker is taking the chairman’s post as part of the financing. New Enterprise Associates led the financing round, which included new investors Lundbeckfonden Ventures, Omega Funds and Aperture Venture Partners, along with TPG Biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.